StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) stock

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)

Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%

Eli Lilly price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Eli Lilly's price to sales ratio was 16.2× on Nov 11, 2026, against 16.3× a year earlier. Over the last 5 years it ranged from 8.0× to 22.7×, with a median of 14.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202616.2×−0.1
2025Dec 31, 202516.3×−0.8
2024Dec 31, 202417.1×+0.7
2023Dec 29, 202316.4×+5.1
2022Dec 30, 202211.3×+2.3
2021Dec 31, 20219.1×+2.4
2020Dec 31, 20206.6×+0.8
2019Dec 31, 20195.8×+0.3
2018Dec 31, 20185.4×+1.5
2017Dec 29, 20174.0×+0.2
2016Dec 30, 20163.7×−0.8
2015Dec 31, 20154.6×+1.3
2014Dec 31, 20143.2×+0.8
2013Jan 31, 20132.5×+0.2
2012Dec 31, 20122.3×–

More Eli Lilly figures

See a number that looks wrong?